Ligand Pharmaceuticals (LGND) Income from Discontinued Operations (2010 - 2023)

Ligand Pharmaceuticals has reported Income from Discontinued Operations for 5 years, with the latest figure at 731000.0 in Q1 2016.

• Quarterly Income from Discontinued Operations changed N/A year-over-year to 731000.0 in Q1 2016, while the trailing twelve-month figure through Mar 2017 was 731000.0 (changed 0.0% YoY) and the FY2013 annual result came in at 2588000.0, up 20.54% from the prior year.
• Income from Discontinued Operations slipped to 731000.0 in Q1 2016 per LGND's latest filing, from 2397000.0 in the prior quarter.
• Over five years, Income from Discontinued Operations peaked at 2397000.0 in Q2 2013 and troughed at 1523000.0 in Q4 2012.
• A 3-year average of 911000.0 and a median of 1265000.0 in 2012 frame the typical range for Income from Discontinued Operations.
• The sharpest annual moves came in 2012 and 2013: Income from Discontinued Operations jumped 46675.0% in 2012, then sank 89.79% in 2013.
• Over 3 years, Income from Discontinued Operations stood at 1523000.0 in 2012, then jumped by 257.39% to 2397000.0 in 2013, then sank by 69.5% to 731000.0 in 2016.
• According to Business Quant data, Income from Discontinued Operations over the past three periods registered 731000.0, 2397000.0, and 191000.0 for Q1 2016, Q2 2013, and Q1 2013 respectively.